ACC 2022 | BENTRACIMAB

This study was presented in phase 2, in a healthy population between 50 and 80 years of age, and it showed the use of Bentracimab reverts the antiplatelet effect of ticagrelor. 

ACC 2022

The study included 205 adults mean age 61, 49% women, previously treated with aspirin and ticagrelor for 48 hrs. who were randomized 3:1 to get bentracimab or placebo, with platelet function measured afterwards. 

Primary end point was minimum percent platelet inhibition within 4 hours and showed a significant advantage in favor of bentracimab (P < 0.0001). There were no differences in adverse events between groups. 

Conclusion

The use of Bentracimab is effective and safe to revert the antiplatelet effect of ticagrelor. Further study is needed to assess clinical efficacy. 

Dr. Andrés Rodríguez

Dr. Andrés Rodríguez.
Member of the Editorial Board of  SOLACI.org .

Reference: Bhatt DL. Bentracimab immediately and significantly reverses the antiplatelet effects of ticagrelor in older people. Presented at: ACC 2022. April 2, 2022. Washington, DC.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

STEACS and the Use of Bivalirudin vs. Heparin: In Search of BRIGHT-4 Outcomes

Various studies and registries have previously shown the impact of post-percutaneous coronary intervention (PCI) complications on the survival of patients with ST-segment elevation acute...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

Ultrathin vs Thin-Strut Stents in PCI Patients at High Bleeding Risk

Several in vivo studies have shown that ultrathin stents present lower thrombogenic risk vs. thin-strut stents, which reflects in lower rates of target lesion...

Should We Withdraw Anticoagulation Before TAVR?

Approximately one-third of patients undergoing transcatheter aortic valve replacement (TAVR) have atrial fibrillation and are on oral anticoagulant (OAC) therapy. This creates a complex...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...